US FDA approves Takeda ’s sNDA for new dose regimen of Alunbrig 180mg tablets

The US Food and Drug Administration (FDA) has approved Takeda Pharmaceutical Company ’s supplemental new drug application (sNDA) for 180mg Alunbrig tablets to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lun…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news